platinum has been researched along with Disease Exacerbation in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 7 (11.67) | 29.6817 |
| 2010's | 35 (58.33) | 24.3611 |
| 2020's | 17 (28.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bar, J; Daher, S; Dudnik, E; Holtzman, L; Keren, S; Moskovitz, M; Nechushtan, H; Reinhorn, D; Rottenberg, Y; Rovitzky, Y; Shochat, T; Urban, D; Wollner, M | 1 |
| Aieta, M; Atzori, F; Bimbatti, D; Carella, C; De Giorgi, U; Di Maio, M; Di Napoli, M; Ermacora, P; Gamba, T; Giannatempo, P; Hamzaj, A; Ignazzi, G; Lolli, C; Masini, C; Pierantoni, F; Pignata, S; Procopio, G; Santini, D; Scandurra, G; Stellato, M; Tambaro, R; Veccia, A; Vignani, F; Zonno, A | 1 |
| Gao, Y; Li, B; Liu, Y; Wang, Y; Zhang, T; Zhang, Z; Zhao, C | 1 |
| Huang, Z; Li, D; Lin, L; Liu, Z; Zhang, G; Zhong, J; Zhuang, W | 1 |
| Augusto, I; Cruz, A; Mansinho, A; Marconi, L; Pinto, C | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Bu, H; Feng, S; Huang, Y; Jin, C; Kong, B; Li, N; Liu, J; Ma, Y; Song, K; Wen, H; Wu, L; Yang, X; Zhang, H | 1 |
| Baldassarre, G; Citron, F; Mongiat, M; Nicoloso, MS; Pellicani, R; Pivetta, E; Poletto, E; Sonego, M; Sorio, R; Vinciguerra, GLR | 1 |
| Alexandris, E; Brustugun, OT; Cuyun Carter, G; Gans, S; Garon, EB; Gautschi, O; Iglesias Docampo, L; Kalofonos, H; Kim, JH; Lee, P; Orlov, SV; Oton, AB; Pérol, M; Reck, M; Scagliotti, GV; Socinski, MA; Stefaniak, VJ; Thomas, M; Wolff, K; Zimmermann, AH | 1 |
| Kågedal, M; Wang, N; Yu, J | 1 |
| Arriola, E; Cui, ZL; Garon, EB; Levy, B; Mekhail, T; Molife, C; Pérol, M; Winfree, KB | 1 |
| Aghajanian, C; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
| Balakrishnan, A; Kumar, P; Prasanna, BK | 1 |
| Bison, B; Gnekow, AK; Hernáiz Driever, P; Kandels, D; Kortmann, RD; Pietsch, T; Schmidt, R; Thomale, UW; Timmermann, B; Warmuth-Metz, M; Witt, O | 1 |
| Avgeris, M; Braicu, I; Dorn, J; Dreyer, T; Loverix, L; Magdolen, V; Magkou, P; Mahner, S; Mavridis, K; Michaelidou, K; Obermayr, E; Panoutsopoulou, K; Reinthaller, A; Scorilas, A; Sehouli, J; Vergote, I; Zeillinger, R | 1 |
| Chang, PM; Chen, HL; Hsin, CH; Huang, WS; Lu, HJ; Peng, CY; Tseng, HC; Tseng, SW; Wu, MF; Yang, MH | 1 |
| Seetharamu, N; Singh, N | 1 |
| Ramkissoon, S; Sorscher, S | 1 |
| Hisada, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Miura, Y; Mori, K; Saito, R; Sakurai, R; Tomizawa, Y | 1 |
| Armstrong, AJ; George, D; Gupta, RT; Harrison, M; Healy, P; Humeniuk, MS; McNamara, M; Ramalingam, S; Wu, Y; Zhang, T | 1 |
| Chuang, A; Cordova, M; Del Valle, Á; Waissbluth, S | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Calabuig-Fariñas, S; Camps, C; Carreras, A; de Cid, R; Duran, X; Galván-Femenía, I; Guindo, M; Jantus-Lewintre, E; Kohno, T; Mercader, JM; Perucho, M; Ramirez, JL; Rosell, R; Sumoy, L; Torrents, D; Yokota, J | 1 |
| Braicu, I; Darb-Esfahani, S; Ganapathi, MK; Ganapathi, RN; Lanchbury, JS; Patel, JN; Reid, J; Sehouli, J; Solimeno, C; Timms, KM; Tshiaba, P | 1 |
| Atkinson, CJ; Győrffy, B; Ham, S; Kawamata, F; Liu, C; Möller, A; Munn, AL; Wei, MQ; Whitehall, V; Wiegmans, AP | 1 |
| Matei, D; Mitra, AK; Mitra, S; Nephew, KP; Wang, Y; Zong, X | 1 |
| Bielenberg, DR; Chang, J; Fernandes, D; Gartung, A; Hammock, BD; Huang, S; Hwang, SH; Kieran, MW; Panigrahy, D; Schmidt, BA; Sukhatme, VP; Yang, J; Zurakowski, D | 1 |
| Fernandes, AW; Pavilack, M; Punekar, RS; Ryan, KJ; Skinner, KE; VanderWalde, NA; Walker, MS | 1 |
| Blackstock, AW; Bogart, JA; Crawford, J; Hodgson, L; Pang, H; Salama, JK; Schild, SE; Urbanic, JJ; Vokes, EE | 1 |
| Brown, R; Dai, W; Masrour, N; Paul, J; Siddiqui, N; Zeller, C | 1 |
| Beesley, VL; Butow, PN; Clavarino, AM; deFazio, A; Green, AC; Horwood, KR; O'Rourke, P; Price, MA; Webb, PM; Wockner, LF; Wyld, DK | 1 |
| Goebell, P; Hegele, A; Matz, U; Neuhaus, T | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Alexandris, E; Arrieta, O; Bidoli, P; Cappuzzo, F; Ciuleanu, TE; Czyzewicz, G; Dakhil, S; Gans, S; Garon, EB; Goksel, T; Gorbunova, V; Grigorescu, A; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lewanski, CR; Orlov, SV; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Sashegyi, A; Syrigos, KN; Thomas, M; Yurasov, S | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Grizas, S; Janciauskiene, R; Juozaityte, E; Jureniene, K; Liutkauskiene, S; Malonyte, R | 1 |
| Chen, W; Fang, Y; Feng, JG; Li, ZP; Mao, WM; Su, D; Xu, XL; Zhang, YP | 1 |
| Arai, G; Eto, M; Itoh, K; Kakuma, T; Komatsu, N; Matsueda, S; Matsumoto, K; Moriya, F; Naito, S; Nasu, Y; Noguchi, M; Ohyama, C; Sasada, T; Suekane, S; Tanaka, M; Uemura, H; Yamada, A | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Borad, MJ; Brunstein, F; Choi, Y; Colon-Otero, G; de Vries, EG; Diamond, JR; Kim, GP; Lamberts, LE; Lieu, CH; Maslyar, DJ; McWilliams, RR; Samineni, D; Scales, SJ; Verheul, HM; Voortman, J; Wang, Y; Weekes, CD | 1 |
| Ayhan, A; Burges, A; Creemers, GJ; Davies, L; Gebski, V; Hilpert, F; Huizing, M; Kristensen, G; Lee, CK; Lindemann, K; Lykka, M; Mirza, MR; Pujade-Lauraine, E; Raspagliesi, F; Romero, I; Rubio, MJ | 1 |
| Al-Radadi, NS; Attia, MS | 1 |
| Enatsu, S; Ferry, D; Hosomi, Y; Kasahara, K; Koue, T; Lee, P; Nakagawa, K; Nakamura, T; Nishio, M; Ohe, Y; Takahashi, T; Tamura, T; Yamada, K; Yamamoto, N; Yoh, K | 1 |
| Basso, U; Basterretxea, L; Bielle, J; Del Muro, XG; Guillot, A; Houédé, N; Lainez, N; Locker, G; Lucas, C; Lusuardi, L; Morelli, F; Parra, HS; Spaeth, D; Tambaro, R; Theodore, C; Tonini, G | 1 |
| Du, G; Fu, ZH; Jin, B; Li, J; Meng, XX; Wang, W; Zhang, SZ; Zhou, BH | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Chu, Z; Gao, G; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Choi, JH; Choi, YW; Han, JH; Hwang, SC; Jeong, SH; Jung, JH; Kang, SY; Kim, JH; Lee, HW; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Fujiwara, H; Hatae, M; Inoue, I; Katabuchi, H; Kodama, S; Kotera, K; Kudo, Y; Masuzaki, H; Onishi, Y; Sueyoshi, K; Suzuki, M; Tajima, A; Tanaka, K; Tashiro, H; Yahata, T; Yoshihara, K | 1 |
| Alexandre, J; Cottu, P; Falandry, C; Floquet, A; Lebrun, D; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Weber, B | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Georgoulias, V; Gioulbasanis, I; Hatzidaki, D; Karampeazis, A; Kotsakis, A; Lerikou, M; Papakotoulas, P; Polyzos, A; Tsiafaki, X; Ziras, N | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Burylo, A; deJong, D; Huitema, AD; Joerger, M; Schellens, JH | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Abbotts, R; Abdel-Fatah, T; Chan, S; Hawkes, C; Madhusudan, S; Seedhouse, C; Sultana, R | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Bak, JY; Bang, YJ; Choi, IS; Heo, DS; Kim, DW; Kim, JH; Kim, NK; Kim, SI; Kim, TY; Kim, YT; Kim, YW; Kwon, JH; Oh, DY; Park, CI; Park, SR; Sung, SW; You, CK | 1 |
| Ferrandina, G; Martinelli, E; Paglia, A; Ranelletti, FO; Scambia, G; Zannoni, GF | 1 |
| Lee, R; Leighl, NB; Loreto, M; Ng, R | 1 |
| Buckner, JC; Erickson, BJ; Gornet, MK; Marks, RS; Scheithauer, BW | 1 |
| Degos, L; Demetri, GD; Dicato, M; Glaspy, J | 1 |
3 review(s) available for platinum and Disease Exacerbation
| Article | Year |
|---|---|
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Urinary Bladder Neoplasms | 2023 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Bibliographic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum; Vinblastine; Vinorelbine | 2009 |
14 trial(s) available for platinum and Disease Exacerbation
| Article | Year |
|---|---|
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Humans; Maintenance Chemotherapy; Platinum; Progression-Free Survival; Urinary Bladder Neoplasms | 2023 |
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Topics: Disease Progression; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Ramucirumab | 2020 |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics.
Topics: Biomarkers, Tumor; CA-125 Antigen; Decision Making; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Membrane Proteins; Models, Theoretical; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Predictive Value of Tests; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sodium-Phosphate Cotransporter Proteins, Type IIb; Software; Topoisomerase II Inhibitors; Treatment Outcome; Tumor Burden | 2020 |
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Radiotherapy Dosage; Small Cell Lung Carcinoma | 2013 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Platinum; Quality of Life; Ramucirumab; Survival Rate; Taxoids | 2014 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Platinum; Retreatment; Treatment Outcome; Urinary Bladder Neoplasms; Vaccines, Subunit | 2016 |
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Immunohistochemistry; Mesothelin; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Response Evaluation Criteria in Solid Tumors | 2016 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Ramucirumab; Retreatment; Risk Factors; Taxoids; Treatment Outcome | 2016 |
Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2010 |
Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
Topics: Anemia; Blood Transfusion; Disease Progression; Dose-Response Relationship, Drug; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hematinics; Hematologic Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Neoplasms; Platinum; Predictive Value of Tests; Prognosis; Quality of Life; Recombinant Proteins; Retrospective Studies; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2002 |
43 other study(ies) available for platinum and Disease Exacerbation
| Article | Year |
|---|---|
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome | 2022 |
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Lung Neoplasms; Pemetrexed; Platinum; Proto-Oncogene Proteins p21(ras) | 2022 |
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence; Retrospective Studies; Ribose | 2023 |
TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Staging; Platinum; Proteomics; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Tumor Microenvironment; Up-Regulation | 2019 |
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Platinum; Ramucirumab; Taxoids | 2021 |
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome | 2020 |
Circulating tumor cell clusters and circulating tumor cell-derived explant models as a tool for treatment response.
Topics: Animals; Antineoplastic Agents; Blood Cells; Disease Progression; Etoposide; Humans; Mice, Nude; Neoplastic Cells, Circulating; Platinum; Small Cell Lung Carcinoma | 2020 |
Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort.
Topics: Adolescent; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease Progression; Female; Germany; Glioma; Humans; Infant; Internationality; Male; Neoplasm Grading; Neurofibromatosis 1; Neurosurgical Procedures; Platinum; Progression-Free Survival; Radiotherapy, Adjuvant; Treatment Failure; Vinblastine | 2020 |
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Survival Analysis; Treatment Outcome; Up-Regulation | 2020 |
Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease Progression; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2021 |
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Lung Neoplasms; Male; Nivolumab; Platinum | 2020 |
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Topics: Adenocarcinoma; BRCA2 Protein; Disease Progression; Germ-Line Mutation; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Platinum; United States | 2021 |
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Taxoids | 2017 |
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Topics: Adenocarcinoma; Aged; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Platinum; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Long term platinum-induced ototoxicity in pediatric patients.
Topics: Adolescent; Antineoplastic Agents; Audiometry; Child; Child, Preschool; Cohort Studies; Disease Progression; Female; Hearing Loss; Humans; Incidence; Infant; Male; Neoplasms; Platinum; Prospective Studies; Surveys and Questionnaires | 2018 |
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genetic Variation; Genome-Wide Association Study; Genotyping Techniques; Germ-Line Mutation; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Spain | 2018 |
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Loss of Heterozygosity; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sequence Analysis, DNA; Young Adult | 2018 |
EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Forkhead Box Protein O3; Humans; Kruppel-Like Transcription Factors; p38 Mitogen-Activated Protein Kinases; Platinum; Prion Proteins; Signal Transduction; Treatment Outcome | 2019 |
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Azacitidine; Cell Line, Tumor; Cytokines; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Therapy; Epigenomics; Female; Humans; Immunotherapy; Interleukin-6; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum; Retinal Dehydrogenase; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment; Up-Regulation | 2018 |
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Disease Progression; Epoxide Hydrolases; Female; Inflammation; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, SCID; Ovarian Neoplasms; Platinum; Signal Transduction; Taxoids | 2019 |
Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Platinum; Proto-Oncogene Proteins p21(ras) | 2019 |
Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CpG Islands; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; Humans; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Promoter Regions, Genetic; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prospective Studies; Quality of Life | 2014 |
Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Recurrence; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome; Young Adult | 2015 |
The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Ribonucleoside Diphosphate Reductase; Risk Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Proteins | 2015 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Progress of pancreatitis disease biomarker alpha amylase enzyme by new nano optical sensor.
Topics: alpha-Amylases; Biomarkers; Disease Progression; Early Diagnosis; Equipment Design; Equipment Failure Analysis; Humans; Luminescent Measurements; Male; Middle Aged; Nanoparticles; Nanotechnology; Optical Devices; Pancreatitis; Platinum; Reproducibility of Results; Sensitivity and Specificity; Thiazoles; Transducers; Young Adult | 2016 |
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Anemia; Disease Progression; Europe; Female; Humans; Kidney Diseases; Liver Neoplasms; Male; Neoplasm Metastasis; Platinum; Practice Guidelines as Topic; Treatment Failure; Urinary Bladder Neoplasms; Urothelium | 2016 |
Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Self Renewal; Cell Transformation, Neoplastic; Disease Progression; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Stem Cells; Platinum; RNA Interference; Wnt Signaling Pathway; Wnt1 Protein | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Pleural Effusion, Malignant; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Japan; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome | 2010 |
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cystadenocarcinoma, Mucinous; Databases, Factual; Disease Progression; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Young Adult | 2010 |
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Predictive Value of Tests; RNA, Messenger; Treatment Outcome; Tubulin; Tumor Suppressor Protein p53 | 2011 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cricetinae; Disease Progression; DNA-Binding Proteins; Female; Gene Expression; Gene Silencing; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; RNA Interference; Treatment Outcome; Tumor Stem Cell Assay; X-ray Repair Cross Complementing Protein 1 | 2013 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Perioperative Care; Platinum; Pneumonectomy; Survival Rate; Treatment Outcome | 2005 |
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2006 |
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Chemotherapy for advanced CNS ependymoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Disease Progression; Ependymoma; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Platinum; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 1999 |